IPF market to be worth $3.6 billion by 2029, says GlobalData

23 November 2020

The idiopathic pulmonary fibrosis (IPF) market was valued at $2.5 billion in 2019 across the seven major markets (7MM), but this figure will reach $3.6 billion by 2029.

So says GlobalData in its report on the market, which it predicts will grow at a compound annual growth rate of 3.8%, driven in particular by the launches of new pipeline agents and increasing use of combination therapy.

"The disease offers a relatively untapped market for drug developers, especially given the high rate of treatment discontinuation"The company’s new report, Idiopathic Pulmonary Fibrosis: Opportunity Analysis and Forecasts to 2029, highlights six launches as important, Galapagos’ (Euronext: GLPG) ziritaxestat, Fibrogen’s (Nasdaq: FGEN) pamrevlumab, Roche’s (ROG: SIX) PRM-151, Galecto’s (Nasdaq: GLTO) TD-139/GB-0139, Bristol Myers Squibb’s (NYSE: BMY) CC-90001, and Liminal Bioscience’s (Nasdaq: LMNL) PBI-4050.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK